• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

前列腺癌患者的免疫调节与免疫治疗：最新综述

Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review.

作者信息

Murray Nigel P

机构信息

Faculty of Medicine, Universidad Finis Terrae, Santiago 7501015, Chile.

Department of Medicine, Hospital de Carabineros de Chile, Santiago 7770199, Chile.

出版信息

Biomedicines. 2025 May 12;13(5):1179. doi: 10.3390/biomedicines13051179.

DOI:10.3390/biomedicines13051179
PMID:40427006
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12109314/
Abstract

Immunotherapy alone or in combination with chemotherapy or radiotherapy is the frontline treatment for melanoma and lung cancer. However, its role in prostate cancer is usually as a fourth-line treatment. It is usually employed in patients with metastasis, after androgen blockade and chemotherapy. This article reviews the immunosuppressive effects of prostate cancer and possible uses of various types of immunotherapies. It also considers when would be the optimal time to employ this type of therapy.

摘要

免疫疗法单独使用或与化疗或放疗联合使用是黑色素瘤和肺癌的一线治疗方法。然而，其在前列腺癌中的作用通常是作为四线治疗。它通常用于已经发生转移、经过雄激素阻断和化疗后的患者。本文综述了前列腺癌的免疫抑制作用以及各种免疫疗法的可能用途。文章还探讨了何时是采用这种治疗方法的最佳时机。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/12109314/e160c9b9b5b6/biomedicines-13-01179-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/12109314/53aa10ac300e/biomedicines-13-01179-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/12109314/4f512466e4a9/biomedicines-13-01179-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/12109314/58383bc91439/biomedicines-13-01179-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/12109314/e160c9b9b5b6/biomedicines-13-01179-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/12109314/53aa10ac300e/biomedicines-13-01179-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/12109314/4f512466e4a9/biomedicines-13-01179-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/12109314/58383bc91439/biomedicines-13-01179-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3435/12109314/e160c9b9b5b6/biomedicines-13-01179-g004.jpg

相似文献

1
Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review.前列腺癌患者的免疫调节与免疫治疗：最新综述
Biomedicines. 2025 May 12;13(5):1179. doi: 10.3390/biomedicines13051179.
2
Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.前列腺癌免疫疗法，尤其是与雄激素剥夺疗法或放射治疗联合使用时。采用定制的药物基因组学方法来克服免疫疗法对癌症的耐药性。
G Chir. 2017 Sep-Oct;37(5):225-235. doi: 10.11138/gchir/2016.37.5.225.
3
Interaction Between Modern Radiotherapy and Immunotherapy for Metastatic Prostate Cancer.现代放疗与免疫疗法在转移性前列腺癌治疗中的相互作用
Front Oncol. 2021 Sep 14;11:744679. doi: 10.3389/fonc.2021.744679. eCollection 2021.
4
Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.免疫疗法治疗转移性前列腺癌：一种规避免疫抑制性肿瘤微环境的方法。
Prostate. 2021 Nov;81(15):1125-1134. doi: 10.1002/pros.24213. Epub 2021 Aug 26.
5
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.联合免疫和雄激素靶向治疗：前列腺癌免疫治疗的新策略
Curr Opin Oncol. 2012 May;24(3):258-65. doi: 10.1097/CCO.0b013e32835205a0.
6
Adapting conventional cancer treatment for immunotherapy.使传统癌症治疗适应免疫疗法。
J Mol Med (Berl). 2016 May;94(5):489-95. doi: 10.1007/s00109-016-1393-4. Epub 2016 Feb 24.
7
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙和泼尼松与或不与恩扎卢胺用于高危非转移性前列腺癌：来自 STAMPEDE 平台方案两项随机对照 3 期试验主要结果的荟萃分析。
Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23.
8
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.转移性去势抵抗性前列腺癌的免疫疗法及免疫疗法联合治疗
Cancers (Basel). 2021 Jan 18;13(2):334. doi: 10.3390/cancers13020334.
9
Endocrine treatment of prostate cancer.前列腺癌的内分泌治疗
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
10
Androgen deprivation and immunotherapy for the treatment of prostate cancer.雄激素剥夺治疗与免疫治疗联合用于前列腺癌的治疗。
Endocr Relat Cancer. 2017 Dec;24(12):T297-T310. doi: 10.1530/ERC-17-0145. Epub 2017 Aug 16.

引用本文的文献

1
Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review.基于放疗或放射性核素的联合治疗以提高晚期前列腺癌免疫治疗疗效的系统评价
J Cancer Res Clin Oncol. 2025 Jun 23;151(6):195. doi: 10.1007/s00432-025-06245-3.

本文引用的文献

1
Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer.单细胞和整体转录组的综合分析揭示了人类前列腺癌中与临床相关的分子亚型。
Chin J Cancer Res. 2025 Jan 30;37(1):90-114. doi: 10.21147/j.issn.1000-9604.2025.01.07.
2
[Analysis of prostate cancer screening results and exploration of screening model for elderly males in Songjiang Rural Areas of Shanghai City based on PSA preliminary screening under the community linkage mode].[基于社区联动模式下PSA初筛的上海市松江区农村地区老年男性前列腺癌筛查结果分析及筛查模式探索]
Zhonghua Yu Fang Yi Xue Za Zhi. 2025 Feb 6;59(2):230-234. doi: 10.3760/cma.j.cn112150-20240906-00710.
3
Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors.
转移性去势抵抗性前列腺癌中免疫检查点抑制剂疗效的生物标志物
Ann Med. 2025 Dec;57(1):2426755. doi: 10.1080/07853890.2024.2426755. Epub 2025 Feb 3.
4
Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer.导管内癌亚型及术后放疗对局限性前列腺癌的预后价值
BMC Urol. 2025 Jan 20;25(1):10. doi: 10.1186/s12894-025-01690-1.
5
Emergence of Neuroendocrine Tumors in Patients Treated with Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.接受雄激素受体通路抑制剂治疗的转移性前列腺癌患者中神经内分泌肿瘤的出现：一项系统评价和荟萃分析。
Eur Urol Oncol. 2025 Apr;8(2):581-590. doi: 10.1016/j.euo.2024.12.014. Epub 2025 Jan 17.
6
PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer.程序性死亡配体1（PD-L1）阳性血小板介导结直肠癌患者对免疫检查点抑制剂的耐药性。
Cell Commun Signal. 2025 Jan 15;23(1):29. doi: 10.1186/s12964-025-02034-0.
7
Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer.前列腺癌中神经内分泌转分化驱动因子的治疗性利用
Cells. 2024 Dec 3;13(23):1999. doi: 10.3390/cells13231999.
8
Cardiotoxicity associated with immune checkpoint inhibitors: Systematic review and meta-analysis.免疫检查点抑制剂相关的心脏毒性：系统评价与荟萃分析。
Crit Rev Oncol Hematol. 2025 Feb;206:104587. doi: 10.1016/j.critrevonc.2024.104587. Epub 2024 Dec 10.
9
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer.前列腺癌中髓系介导的免疫治疗耐药性的演变
Nature. 2025 Jan;637(8048):1207-1217. doi: 10.1038/s41586-024-08290-3. Epub 2024 Dec 4.
10
A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer.一例快速进展的原发性转移性小细胞神经内分泌前列腺癌病例。
Case Rep Oncol Med. 2024 Sep 17;2024:7998149. doi: 10.1155/2024/7998149. eCollection 2024.